- Home
- LGMK vs TNFA Comparison
LGMK vs TNFA Comparison
Compare LGMK & TNFA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGMK
- TNFA
- Stock Information
- Founded
- LGMK 2011
- TNFA 2014
- Country
- LGMK United States
- TNFA United States
- Employees
- LGMK N/A
- TNFA N/A
- Industry
- LGMK Industrial Specialties
- TNFA
- Sector
- LGMK Health Care
- TNFA
- Exchange
- LGMK Nasdaq
- TNFA NYSE
- Market Cap
- LGMK 3.5M
- TNFA 3.2M
- IPO Year
- LGMK N/A
- TNFA N/A
- Fundamental
- Price
- LGMK $1.41
- TNFA $1.16
- Analyst Decision
- LGMK
- TNFA
- Analyst Count
- LGMK 0
- TNFA 0
- Target Price
- LGMK N/A
- TNFA N/A
- AVG Volume (30 Days)
- LGMK 304.5K
- TNFA 297.1K
- Earning Date
- LGMK 11-12-2024
- TNFA 11-14-2024
- Dividend Yield
- LGMK N/A
- TNFA N/A
- EPS Growth
- LGMK N/A
- TNFA N/A
- EPS
- LGMK N/A
- TNFA N/A
- Revenue
- LGMK $10,078,502.00
- TNFA N/A
- Revenue This Year
- LGMK $1.54
- TNFA N/A
- Revenue Next Year
- LGMK N/A
- TNFA N/A
- P/E Ratio
- LGMK N/A
- TNFA N/A
- Revenue Growth
- LGMK 4.44
- TNFA N/A
- 52 Week Low
- LGMK $1.32
- TNFA $1.05
- 52 Week High
- LGMK $32.25
- TNFA $5.91
- Technical
- Relative Strength Index (RSI)
- LGMK 38.44
- TNFA 44.65
- Support Level
- LGMK $1.32
- TNFA $1.12
- Resistance Level
- LGMK $1.49
- TNFA $1.52
- Average True Range (ATR)
- LGMK 0.15
- TNFA 0.12
- MACD
- LGMK 0.01
- TNFA -0.00
- Stochastic Oscillator
- LGMK 20.79
- TNFA 12.20
About LGMK LogicMark Inc. (NV)
LogicMark Inc provides personal emergency response systems (PERS), health communications devices, and IoT technologies to create a connected care platform. Its devices give people the ability to receive care at home and confidence to age in place. The company incorporates two-way voice communication technology directly into its medical alert pendant and provides this life-saving technology at a price point that everyday consumers can afford.
About TNFA TNF PHARMACEUTICALS INC EFFEC
TNF Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. The company is developing and commercializing two therapeutic platforms. MyMD-1 is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-CBD is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and monoamine oxidase enzyme type B.